Dr. Jamali's research interests include effect of pathophysiological changes on the action and disposition of drugs, stereochemical aspects of drugs action and disposition, basic and clinical pharmacology of anti-rheumatic, analgesic and cardiovascular drugs, and toxicology of nonsteroidal antiinfammatory drugs. He has trained 36 PhDs and published many refereed articles (H-Score, 42).
Recently one of Jamali's inventions, GLUCOSAMINE PR0-DRUGS has been patented: USA # 8,772,227.
Selected published work:
W Asghar, F Jamali (2015) The effect of COX-2-selective meloxicam on the myocardial, vascular and renal risks: a systematic review. Inflammopharmacology.23(1):1-16. doi: 10.1007/s10787-014-0225-9.
W Asghar, E Pittman, F Jamali (2015) Comparative efficacy of esomeprazole and omeprazole: Racemate to single enantiomer switch.Daru J Pharrm Sci. .23:50, 1-7. doi: 10.1186/s40199-015-0133-6.
A Aghazadeh-Habashi, W Asghar, F Jamali (2015) Simultaneous determination of selected eicosanoids by reversed-phase HPLC method using fluorescence detection and application to rat and human plasma, and rat heart and kidney samples. J Pharm Biomed Anal. 110:12-9. doi: 10.1016.
A Aghazadeh-Habashi, MH Gilzad-Kohan , W Asghar, F Jamali (2014) Glucosamine Dose/Concentration-Effect Correlation in the Rat with Adjuvant Arthritis. J Pharm Sci. 103:760-767.
S Harirforoosh, W Asghar, F Jamali (2013) Adverse Effects of Nonsteroidal Anti-inflammatory Drugs: An Update of Gastrointestinal, Cardiovascular and Renal Complications. J Pharm Pharm Sci. 16: 821-847.
A Aghazadeh-Habashi, F Jamali (2011) The glucosamine controversy; a pharmacokinetic issue. J Pharm Pharm Sci, 14: 264 - 273, 2011.
F Sanaee; F Jamali (2014) Action and disposition of the β3-agonist nebivolol in presence of inflammation; an alternative to conventional β1-blockers. Current Pharmaceutical Design. Special issue on Cardio-metabolic Complication. Curr Pharm Des. 2014: 20(9):1311-7.
F Sanaee, JD Clements, AWG Waugh, RN Fedorak, R Lewanczuk, F Jamali (2011) Crohn’s Disease elevates plasma concentrations of S-verapamil but reduces response to the drug proportional to disease activity. Brit J Clin Pharmacol, 72:787-97.
F Jamali (2007) Arthritis is associated with cardiovascular disease in the users of analgesics and nonsteroidal anti-inflammatory drugs. Arch Intern Med 167: 2371-2.
A peer-reviewed letter.
S Hanafy, N Dagenais, WF Dryden, F Jamali (2007) The effects of Angiotensin II receptor type I blockade on Inflammation-Induced Alterations of Pharmacokinetics and Pharmacodynamics of calcium channel blockers. Brit J Pharmacol 153: 90-99.
KM Kulmatycki, F Jamali. (2006)R Drug disease interactions: Role of inflammatory mediators in depression and variability in drug response. J Pharm Pharm Sci, 9:292-306.
N Daneshtalab, RZ Lewanczuk, AS Russell, F Jamali (2006) Losartan Effect Is Not Down-Regulated by Rheumatoid Arthritis. J Clin Pharmacol, 46:1344-1355.
N Dagenais, F Jamali (2005) Protective Effects of Angiotensin II Interruption: Evidence for Anti-inflammatory Actions. Pharmacotherapy, 25:1213-29.
S Harirforoosh, A Aghazadeh-Habashi, Fakhreddin Jamali* (2006) The extent of renal effect of COX-2-selective inhibitors is pharmacokinetic-dependent. Clinical and Experimental Pharmacology and Physiology. 33: 917-924.
PR Mayo, K Skeith, AS Russell, F Jamali (2000) Decreased dromotropic response to verapamil despite pronounced increased drug concentration in rheumatoid arthritis. Br J Clin Pharmacol 50:605-13.
LA Eliot, F Jamali (1999) Pharmacokinetics and Pharmacodynamics of Nifedipine in Atorvastatin Treated Hyperlipidemia in the Rat. J Pharmacol Exp Ther, 291:188-193.
F Jamali* CM Kunz (1999) Pain-Mediated altered Absorption and Metabolism: An Explanation for Delayed Onset of Analgesia. Br J Clin Pharmacol, 47:391-396.
F Jamali (1992) Enantioselective versus non-enantioselective assays in comparative bioavailability studies with racemic drugs. Biopharm Drug Dispos, 13: 385-387.
F Jamali; R Mehvar; FM Pasutto (1989) Stereospecific Aspects of Drug Action and Disposition: Therapeutic Pitfalls. J Pharm Sci, 78: 695 715.